A detailed history of New Edge Advisors, LLC transactions in Catalent, Inc. stock. As of the latest transaction made, New Edge Advisors, LLC holds 19 shares of CTLT stock, worth $1,206. This represents 0.0% of its overall portfolio holdings.

Number of Shares
19
Previous 19 -0.0%
Holding current value
$1,206
Previous $1,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 15, 2024

SELL
$53.58 - $57.02 $3,911 - $4,162
-73 Reduced 79.35%
19 $1,000
Q1 2024

May 14, 2024

SELL
$42.56 - $59.82 $13,363 - $18,783
-314 Reduced 77.34%
92 $5,000
Q4 2023

Feb 13, 2024

BUY
$32.18 - $46.57 $11,874 - $17,184
369 Added 997.3%
406 $18,000
Q2 2023

Aug 14, 2023

BUY
$31.86 - $67.26 $1,178 - $2,488
37 New
37 $1,000
Q4 2022

Feb 14, 2023

BUY
$41.39 - $81.0 $34,229 - $66,987
827 New
827 $37,000
Q3 2017

Nov 13, 2017

SELL
$33.75 - $41.67 $11,137 - $13,751
-330 Closed
0 $0
Q2 2017

Aug 16, 2017

BUY
N/A
330
330 $0

Others Institutions Holding CTLT

About Catalent, Inc.


  • Ticker CTLT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 179,896,000
  • Market Cap $11.4B
  • Description
  • Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products,...
More about CTLT
Track This Portfolio

Track New Edge Advisors, LLC Portfolio

Follow New Edge Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New Edge Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on New Edge Advisors, LLC with notifications on news.